CXCL13 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients [Letter]

Mingyu Wei, 1 Zuowei Duan 2 1Medical College of Yangzhou University, Yangzhou 225000, Jiangsu, People’s Republic of China; 2Department of Neurology, The Affiliated Hospital of Yangzhou University, Yangzhou 225000, Jiangsu, People’s Republic of ChinaCorrespondence: Zuowei DuanEm...

Full description

Bibliographic Details
Main Authors: Wei M, Duan Z
Format: Article
Language:English
Published: Dove Medical Press 2020-01-01
Series:Neuropsychiatric Disease and Treatment
Subjects:
Online Access:https://www.dovepress.com/letter-cxcl13-is-a-biomarker-of-anti-leucine-rich-glioma-inactivated-p-peer-reviewed-article-NDT
Description
Summary:Mingyu Wei, 1 Zuowei Duan 2 1Medical College of Yangzhou University, Yangzhou 225000, Jiangsu, People’s Republic of China; 2Department of Neurology, The Affiliated Hospital of Yangzhou University, Yangzhou 225000, Jiangsu, People’s Republic of ChinaCorrespondence: Zuowei DuanEmail jydzw061344@163.comWe recently read the original report by Lin and colleagues with great interest. In this study, the authors concluded that both serum and cerebrospinal fluid (CSF) levels of CXCL13, a B cell chemotactic factor, were significantly higher in patients with anti-leucine-rich glioma-inactivated protein 1 (anti-LGI1) encephalitis compared to non-inflammatory neurologic disorder control groups. 1 However, we have some concerns about the interpretation of their data.View the original paper by Lin and colleagues.
ISSN:1178-2021